Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1825-1829

  Mozaffarian, Neelufar ^a   Berman, Joan W ^a   Casadevall, Arturo ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Ullman Building 1219 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIBODY; GAMMA INTERFERON; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; POLYSACCHARIDE; RNA; VIRULENCE FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; MACROPHAGE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYNTHESIS;

EID: 0030855543     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1825     Document Type: Article

References (53)

1. Alspaugh, J. A., and D. L. Granger. 1991. Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect. Immun. 59:2291-2296.
2. Aslanzadeh, J., J. S. Mormol, and J. R. Little. 1991. Anticryptococcal activity of amphotericin B-stimulated macrophages. Immunopharmacol. Immunotoxicol. 13:465-483.
3. Belay, T., R. Cherniak, E. B. O'Neill, and T. R. Kozel. 1996. Serotyping of Cryptococcus neoformans by dot enzyme assay. J. Clin. Microbiol. 34:466-470.
4. Bhattacharjee, A. K., J. E. Bennett, and C. P. Glaudemans. 1984. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 6:619-624.
5. Brajtburg, J., W. G. Powderly, G. S. Kobayashi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:183-188.
6. Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol. 14:4912-4919.
7. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
8. Chia, J. K., and M. Pollack. 1989. Amphotericin B induces tumor necrosis factor production by murine macrophages. J. Infect. Dis. 159:113-166.
9. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
10. Diamond, R. D., and J. E. Bennett. 1974. Prognostic factors in cryptococcal meningitis. Ann. Intern. Med. 80:176-181.
11. Drapier, J.-C., J. Wietzerbin, and J. B. Hibbs, Jr. 1988. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol. 18:1587-1592.
12. Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:1114-1120.
13. Dromer, F., A. Varma, O. Ronin, S. Mathoulin, and B. Dupont. 1994. Molecular typing of Cryptococcus neoformans serotype D clinical isolates. J. Clin. Microbiol. 32:2364-2371.
14. Dumarey, C. H., V. Labrousse, N. Rastogi, B. B. Vargaftig, and M. Bachelet. 1994. Selective Mycobacterium avium-induced production of nitric oxide by human monocyte-derived macrophages. J. Leukocyte Biol. 56:36-40.
15. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790-799.
16. Fromtling, R. A., H. K. Shadomy, and E. S. Jacobson. 1982. Decreased virulence in stable acapsular mutants of Cryptococcus neoformans. Mycopathologia 79:23-29.
17. Goldman, D., Y. Cho, M. Zhao, A. Casadevall, and S. C. Lee. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148:1275-1282.
18. Gordon, M. A., and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114:373-378.
19. Granger, D. L., J. B. Hibbs, Jr., J. R. Perfect, and D. T. Durack. 1988. Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J. Clin. Invest. 81:1129-1136.
20. Graybill, J. R., P. C. Craven, L. F. Mitchell, and D. J. Drutz. 1978. Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis. Antimicrob. Agents Chemother. 14:659-667.
21. Herrmann, J. L., N. Dubois, M. Fourgeaud, D. Basset, and P. H. Lagrange. 1994. Synergic inhibitory activity of amphotericin-B and γ interferon against intracellular Cryptococcus neoformans in murine macrophages. J. Antimicrob. Chemother. 34:1051-1058.
22. Joly, V., L. Saint-Julien, C. Carbon, and P. Yeni. 1994. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J. Infect. Dis. 170:1331-1334.
23. Kozel, T. R., and J. Cazin. 1971. Nonencapsulated variant of Cryptococcus neoformans. I. Virulence studies and characterization of soluble polysaccharide. Infect. Immun. 3:287-294.
24. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
25. Lee, S. C., D. W. Dickson, and A. Casadevall. 1996. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Human Pathol. 27:839-847.
26. Lee, S. C., A. Casadevall, and D. W. Dickson. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol. 148:1267-1274.
27. Lee, S. C., D. W. Dickson, C. F. Brosnan, and A. Casadevall. 1994. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J. Exp. Med. 180:365-369.
28. Lovchik, J., M. Lipscomb, and C. R. Lyons. 1997. Expression of lung inducible nitric oxide synthase protein does not correlate with nitric oxide production in vivo in a pulmonary immune response against Cryptococcus neoformans. J. Immunol. 158:1772-1778.
29. Manthey, C. L., P. Y. Perera, C. A. Salkowski, and S. N. Vogel. 1994. Taxol provides a second signal for murine macrophage tumoricidal activity. J. Immunol. 152:825-831.
30. Mautino, G., N. Paul-Eugene, P. Chanez, A. M. Vignola, J. P. Kolb, J. Bousquet, and B. Dugas. 1994. Heterogenous spontaneous and interleukin-4-induced nitric oxide production by human monocytes. J. Leukocyte Biol. 56:15-20.
31. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-γ-stimulated murine macrophage-like J774.16 cells. J. Leukocyte Biol. 57:657-662.
32. Mukherjee, J., A. Casadevall, and M. D. Scharff. 1993. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1105-1116.
33. Mukherjee, J., L. S. Zuckier, M. D. Scharff, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580-587.
34. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Monoclonal antibody-based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154: 27-35.
35. Nicholson, S., M. G. Bonecini-Almeida, J. R. Lapa e Silva, C. Nathan, Q. Xie, R. Mumford, J. R. Weidner, J. Calaycay, J. Geng, N. Boechat, C. Linhares, W. Rom, and J. L. Ho. 1996. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 183: 2293-2302.
36. Perfect, J. R., D. L. Granger, and D. T. Durack. 1987. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 156:316-323.
37. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
38. Powderly, W. G., G. A. Cloud, W. E. Dismukes, and M. S. Saag. 1994. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 18:789-792.
39. Reiner, S. L., Z. Shichun, D. B. Corry, and R. M. Locksley. 1993. Constructing polycompetitor cDNAs for quantitative PCR. J. Immunol. Methods 165:37-46.
40. Spitzer, E. D., S. G. Spitzer, L. F. Freundlich, and A. Casadevall. 1993. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 341:595-596.
41. Stein, S. H., J. R. Little, and K. D. Little. 1987. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell. Immunol. 105:99-109.
42. Tohyama, M., K. Kawakami, M. Futenma, and A. Saito. 1996. Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin. Exp. Immunol. 103:436-441.
43. Tohyama, M., K. Kawakami, and A. Saito. 1996. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40:1919-1923.
44. Tokuda, Y., M. Tsuji, M. Yamazaki, S. Kimura, S. Abe, and H. Yamaguchi. 1993. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37:2228-2230.
45. Vecchiarelli, A., G. Verducci, S. Perito, P. Puccetti, P. Marconi, and F. Bistoni. 1986. Involvement of host macrophage in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J. Antibiot. 39:846-855.
46. Vecchiarelli, A., D. Pietrella, M. Dottorini, C. Monari, C. Retini, T. Todisco, and F. Bistoni. 1994. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98:217-223.
47. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect. Immun. 63:2919-2923.
48. Wolf, J. E., and S. E. Massof. 1990. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58: 1296-1300.
49. Wolf, J. E., S. H. Stein, K. D. Little, A. L. Abegg, and J. R. Little. 1991. Amphotericin B selectively stimulates macrophages from high responder mouse strains. Immunopharmacol. Immunotoxicol. 13:221-235.
50. Yamaguchi, H., S. Abe, and Y. Tokuda. 1993. Immunomodulating activity of antifungal drugs. Ann. N. Y. Acad. Sci. 685:447-457.
51. Zebedee, S. L., R. K. Koduri, J. Mukherjee, S. Mukherjee, S. Lee, D. F. Sauer, M. D. Scharff, and A. Casadevall. 1994. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob. Agents Chemother. 38:1507-1514.
52. Zinetti, M., G. Fantuzzi, R. Delgado, E. DiSanto, P. Ghezzi, and M. Fratelli. 1995. Endogenous nitric oxide production by human monocytic cells regulates LPS-induced TNF production. Eur. Cytokine Netw. 6:45-48.
53. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.